Fulvestrant

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4488 publications

Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.

Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.

Journal: Expert opinion on drug metabolism & toxicology

Published: July 24, 2026

Vepdegestrant (Veppanu) for advanced breast cancer.

Vepdegestrant (Veppanu) for advanced breast cancer.

Journal: The Medical letter on drugs and therapeutics

Published: July 14, 2026

MicroRNA Signatures of Fulvestrant-Treated Luminal Breast Cancer Cells: Identification of Therapeutic Targets Regulated by miR-374b-5p.

MicroRNA Signatures of Fulvestrant-Treated Luminal Breast Cancer Cells: Identification of Therapeutic Targets Regulated by miR-374b-5p.

Journal: International journal of molecular sciences

Published: June 29, 2026

Capivasertib for locally advanced or metastatic breast cancer.

Capivasertib for locally advanced or metastatic breast cancer.

Journal: Australian prescriber

Published: June 18, 2026

Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.

Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 15, 2026

Adverse Events as a Surrogate of Sufficient Pharmacological Exposure in Metronomic Combination Chemotherapy: Extended Real-World Cohort Analysis of the FulVEC Regimen in Metastatic ER+/HER2- Breast Cancer.

Adverse Events as a Surrogate of Sufficient Pharmacological Exposure in Metronomic Combination Chemotherapy: Extended Real-World Cohort Analysis of the FulVEC Regimen in Metastatic ER+/HER2- Breast Cancer.

Journal: Cancers

Published: June 12, 2026

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 04, 2026

Early Distant Metastasis in Synchronous Bilateral Breast Cancer including a Small Low-Grade Carcinoma with Osteoclast-Like Giant Cells: A Case Report.

Early Distant Metastasis in Synchronous Bilateral Breast Cancer including a Small Low-Grade Carcinoma with Osteoclast-Like Giant Cells: A Case Report.

Journal: Surgical case reports

Published: May 26, 2026

Early-onset, treatment-cycle-linked hyperinsulinaemic insulin resistance during capivasertib therapy: a case report.

Early-onset, treatment-cycle-linked hyperinsulinaemic insulin resistance during capivasertib therapy: a case report.

Journal: Cardiovascular diabetology. Endocrinology reports

Published: May 25, 2026

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer.

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.

Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer.

The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer.

Journal: Drug discovery today

Published: May 23, 2026

Showing 1-12 of 4,488

Last Updated: 09/26/2026